Renil Rodriguez Martinez, MD
Endocrinology, Diabetes & Metabolism · la Jolla, CANPI 1477817757
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Medtronic at 36.0% of the total. Reporting peaked in 2023 at $4,155 and has fallen 80.1% since, to $828 in 2025.
Across 192 payments — averaging $61.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Ascensia Diabetes Care US Inc.$3K
- AstraZeneca$829
- Tandem Diabetes Care, Inc.$581
- Boehringer Ingelheim$438
- Novo Nordisk$431
- plus $2K from 13 others
Across 37 payments — averaging $9685.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$232K
- Eli Lilly Export S.A. Puerto Rico Branch$121K
- Eli Lilly$5K
What the payments were for
- Consulting fees$3,52530%
- Travel & lodging$3,30528%
- Food & beverage$4,96242%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 42 | $4,275 |
| Ascensia Diabetes Care US Inc. | 6 | $3,425 |
| AstraZeneca(2 entities) | 24 | $829 |
| Tandem Diabetes Care, Inc. | 2 | $581 |
| Boehringer Ingelheim | 17 | $438 |
| Novo Nordisk | 22 | $431 |
| Eli Lilly Export S.A. Puerto Rico Branch | 15 | $415 |
| Dexcom, Inc. | 19 | $349 |
| Amgen | 10 | $240 |
| Abbott | 7 | $238 |
| Lilly USA, LLC | 10 | $233 |
| Corcept Therapeutics | 3 | $162 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| AbbVie | 3 | $62 |
| Merck | 2 | $35 |
| Antares Pharma, Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Mannkind Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,683
- Minimed 670G System$903
- t-slim insulin pump$525
- MINIMED 780G$474
- FARXIGA$250
- Korlym$125
- ZEPBOUND$119
- FreeStyle Libre 2$108
- LOKELMA$102
How this compares
$11,876 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 372 | $379,660 |
| TrulicityDulaglutide | 222 | $237,901 |
| MounjaroTirzepatide | 199 | $215,238 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 172 | $123,165 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 117 | $80,145 |
| Jentadueto XrLinagliptin/Metformin Hcl | 122 | $64,911 |
| JardianceEmpagliflozin | 98 | $63,001 |
| FarxigaDapagliflozin Propanediol | 63 | $47,232 |
| JanuviaSitagliptin Phosphate | 56 | $35,244 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 51 | $34,436 |
| TradjentaLinagliptin | 64 | $34,093 |
| SynthroidLevothyroxine Sodium | 520 | $32,753 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $19,169 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $15,929 |
| LantusInsulin Glargine,hum.Rec.Anlog | 106 | $10,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Insulin Lispro | $233 | $465,504540 claims |
| Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jentadueto Xr, Jardiance, Tradjenta | $438 | $385,762606 claims |
| Novo NordiskOzempic | $431 | $379,660372 claims |
| MerckJanuvia, Janumet Xr | $35 | $69,680107 claims |
| AstraZenecaFarxiga | $829 | $47,23263 claims |
| AbbVieSynthroid | $62 | $32,753520 claims |
| Sanofi-aventis U.S. LLCLantus | $83 | $10,992106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in la Jolla
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
- Matthew Levinela Jolla$134K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.